Cardiff Oncology, Inc. (CRDF)
Market Cap | 181.63M |
Revenue (ttm) | 488,000 |
Net Income (ttm) | -41.47M |
Shares Out | 44.68M |
EPS (ttm) | -0.93 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 116,224 |
Open | 4.060 |
Previous Close | 3.990 |
Day's Range | 3.980 - 4.085 |
52-Week Range | 0.940 - 6.420 |
Beta | 1.97 |
Analysts | Strong Buy |
Price Target | 10.50 (+158.94%) |
Earnings Date | May 2, 2024 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufact... [Read more]
Financial Performance
In 2023, CRDF's revenue was $488,000, an increase of 26.42% compared to the previous year's $386,000. Losses were -$41.47 million, 7.07% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CRDF stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 158.94% from the latest price.
News
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m.
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vasculariz...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite -
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting -
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m.
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
- Findings from the Phase 1b portion of company's Phase 1b/2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care - - ...
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
SAN DIEGO , Nov. 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
- Advance to first-line RAS-mutated metastatic colorectal cancer (mCRC) for lead program based on positive clinical and preclinical data and guidance from FDA - - Expanded relationship with Pfizer, w...
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
- Management will hold a conference call on Thursday, November 2 at 4:30 p.m. ET/1:30 p.m.
Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks
Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% (vs.
Cardiff Oncology to Present at Upcoming Investor Conferences in September
SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
- New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship; interim topline data expected in mid-2024 - - Advance to first-line mCRC follows stro...
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - - First-line mCRC represents substantial increase in patient impact...
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , July 24, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...
Cardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO , June 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop nov...
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (...
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
SAN DIEGO , March 28, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop n...
Cardiff Oncology Formally Introduces Scientific Advisory Board
- SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research – - SAB will continue to provide insight and guidance on the ...
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective response rate, durability and progression-f...
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib Served as the lead investigator for two pr...